Clinical trial
Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic…
NCT00154882 · National Taiwan University Hospital, Other · Unknown status
Key facts
| NCT number | NCT00154882 |
|---|---|
| Title | Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer |
| Official title | Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer |
| Lead sponsor | National Taiwan University Hospital, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel (Phyxol), Cisplatin |
| Enrollment | 43 |
| Start date | Sep 1, 2003 |
| Completion | Jul 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 21, 2010 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: